Eli Lilly: SOFE-M Plus Bevacizumab Shows 79% Confirmed ORR in Ovarian Cancer

A 79% confirmed ORR is a striking efficacy signal, but the disclosure is thin on the context that determines what it actually means: no comparator arm, no prior-treatment breakdown, and no clarity on how many patients the rate rests on. That matters most for the ovarian cancer field, where bevacizumab is already a familiar backbone and the bar for a new combination is set by how it performs against existing regimens, not in isolation. Whether fuller trial detail and any regulatory path follow is the open question.